Literature DB >> 7075676

Do phenytoin and carbamazepine depress excitation and/or facilitate inhibition?

G H Fromm, A S Chattha, C F Terrence, J D Glass.   

Abstract

The effect of phenytoin and carbamazepine on the segmental and the periventricular inhibition was investigated in interneurons of the spinal trigeminal nucleus oralis of cats. The segmental inhibition was elicited by delivering a conditioning stimulus to the maxillary nerve 100 ms prior to the test stimulus to the maxillary nerve, and the periventricular inhibition was elicited by delivering a conditioning stimulus to the periventricular gray matter. Therapeutic serum levels of phenytoin and carbamazepine facilitated the segmental inhibition, but depressed the periventricular inhibition, while also depressing the response of trigeminal nucleus neurons to an unconditioned maxillary nerve stimulus. These results indicate that the depression of neural activity by phenytoin and carbamazepine is selective, leaving some inhibitory pathways relatively untouched and thus greatly enhancing their effectiveness. It is suggested that the anticonvulsant properties of phenytoin and carbamazepine are due to their ability to produce a relative facilitation of inhibitory feedback mechanisms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7075676     DOI: 10.1016/0014-2999(82)90482-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  The treatment of trigeminal neuralgia.

Authors:  R L Busch
Journal:  Anesth Prog       Date:  1987 Nov-Dec

Review 2.  Mechanisms of anticonvulsant drug action. I. Drugs primarily used for generalized tonic-clonic and partial epilepsies.

Authors:  C L Faingold; R A Browning
Journal:  Eur J Pediatr       Date:  1987-01       Impact factor: 3.183

Review 3.  Carbamazepine toxicity and poisoning. Incidence, clinical features and management.

Authors:  L Durelli; U Massazza; R Cavallo
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.